News and Announcements
Proteomics International’s PromarkerD Test Latest Comprehensive Update
- Published April 04, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Proteomics International Laboratories Ltd (ASX: PIQ) (PILL), the leader in predictive diagnostics for diabetic kidney disease, presents a comprehensive update on the commercialisation progress for its PromarkerD test.
KEY TAKEAWAYS:
- PromarkerD rated the world’s leading diagnostic test for diabetic kidney disease by global market research firm Frost & Sullivan;
- First licensing income received;
- Key patents secured and extended;
- Clinical laboratory prototype manufacture on target for mid-2017;
- First commercial sales are targeted for the end of 2017;
- Validation study completed – announcement of results pending publication of the prior predictive development study;
- Development study shows PromarkerD correctly predicts 95% of otherwise healthy diabetics who will develop chronic kidney disease;
- Discussions continue with prospective diagnostic companies in the USA, China, Europe, Australia and Japan to secure licences for the commercialisation of PromarkerD.
PromarkerD is a predictive diagnostic test for diabetic kidney disease. In a clinical study PromarkerD correctly predicted 95% of otherwise healthy diabetics who went on to develop chronic kidney disease within four years. PromarkerD was last month rated the world’s leading diagnostic test for diabetic kidney disease in the Frost & Sullivan report Biomarkers Enabling Diabetes and Obesity Management.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
